Medicaid Programs Should Be Able To ‘Compel’ Value-Based Contracts, State Association Official Says
Existing value-based contracts, which are voluntary for manufacturers, do not lower costs for states, National Association of Medicaid Directors executive director Matt Salo suggests.
You may also be interested in...
As MACPAC moves toward formal recommendations, a CBO analysis finds that differential Medicaid rebates for drugs approved through the accelerated pathway could save the federal government up to $1bn over five years.
Demonstration, which may not survive scrutiny from the Biden Administration, includes some protections, such as prohibiting Tennessee from excluding drugs described in the Medicare Part D protected classes policy.
Innovative purchasing model is not designed to solve the problem of high drug costs, experts point out during a recent discussion at the Brookings Institution.